Keywords: akorn, cipla, enter, accord, transplant, rejection, drug

Akorn and Cipla enter accord for transplant rejection drug

Article | 02 July 2007

Print This

USA-based Akorn and Cipla, a leading Indian pharmaceutical company located in Mumbai, have signed an exclusive drug development and supply ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in